In addition, overexpression of ERK5 has been identified in various types of cancer, including breast and prostate cancer and oral squamous cell carcinoma, and has been hypothesized to represent an independent prognostic biomarker of disease-free survival (11,29,30). Here, MAPK7 is linked to prostate cancer.